These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Clinical and hematological characteristics and MOPP tolerance of patients with Hodgkin's lymphoma in the bone marrow]. Fiacchini M; Lauria F; Mazza P; Tura S Haematologica; 1982 Jun; 67(3):394-401. PubMed ID: 6814996 [No Abstract] [Full Text] [Related]
4. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV]. Lopez M Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542 [No Abstract] [Full Text] [Related]
5. [Experience with the management of patients with therapy-resistant Hodgkin's disease]. Berényi E; Szegedi G Orv Hetil; 1984 Nov; 125(45):2737-40, 2743. PubMed ID: 6548560 [No Abstract] [Full Text] [Related]
6. [Chemotherapy of Hodgkin disease with modified MOPP]. Amiel JL; Spielmann M; Kerbrat P; Droz JP; Tursz T; Ben Ayed F Schweiz Rundsch Med Prax; 1983 Feb; 72(6):190-3. PubMed ID: 6687638 [No Abstract] [Full Text] [Related]
8. Chemotherapy of Hodgkin's disease in studies by acute leukemia group B. Nissen NI; Stutzman L; Holland JF; Glidewell OJ Arch Intern Med; 1973 Mar; 131(3):396-401. PubMed ID: 4688038 [No Abstract] [Full Text] [Related]
9. [Hodgkin's disease: treatment of clinical stages II3+A, IB, IIB, IIIA and IIIB with short chemotherapy (3 MOPP, or 3 CVPP), splenectomy and limited irradiation. Results after 4 years of a prospective protocol including 94 patients]. Andrieu JM; Casassus P; Coscas Y; Darmont J; Goubeau C; Katz M; Jacquillat C; Tricot G; Weil M Bull Cancer; 1982; 69(4):321-9. PubMed ID: 6897520 [No Abstract] [Full Text] [Related]
10. Splenectomy effects on chemotherapy in Hodgkin's disease. Panettiere F; Coltman CA Arch Intern Med; 1973 Mar; 131(3):362-6. PubMed ID: 4688035 [No Abstract] [Full Text] [Related]
11. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754 [TBL] [Abstract][Full Text] [Related]
12. [Results with MOPP combination chemotherapy in Hodgkin's disease (author's transl)]. Neumann E Wien Klin Wochenschr; 1981 Feb; 93(4):134-7. PubMed ID: 6895134 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of lymphogranulomatosis]. Baĭsogolov GD Med Radiol (Mosk); 1982 Sep; 27(9):83-9. PubMed ID: 6897278 [No Abstract] [Full Text] [Related]
14. [Results of combined chemotherapy (MOPP) in the treatment of patients with generalized Hodgkin's disease]. Aghai E; Kende G; Many A; Ramot B Harefuah; 1974 Apr; 86(7):348-51. PubMed ID: 4846045 [No Abstract] [Full Text] [Related]
15. [Treatment of recurrences of lymphogranulomatosis]. Kovryzhkina TA Med Radiol (Mosk); 1984 Jan; 29(1):35-9. PubMed ID: 6546406 [No Abstract] [Full Text] [Related]
16. [Purpura fulminans in a splenectomized patient]. Dubouloz E; Domergue R; Francois G; Charrel M; Michaud A; Levy G Nouv Presse Med; 1978 Nov; 7(38):3459. PubMed ID: 740533 [No Abstract] [Full Text] [Related]
17. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
18. [Cytostatic chemotherapy in lymphogranulomatosis]. Stacher A Med Klin; 1973 Jul; 68(30):985-8. PubMed ID: 4131695 [No Abstract] [Full Text] [Related]
19. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]